AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
For someone looking at DRDGOLD, the core belief is that a focused tailings retreatment business with high returns on equity and solid recent earnings momentum can keep translating throughput into cash, even as individual quarters remain noisy. The big near term catalysts had largely centred on confirming the strong EPS guidance for 2025 and the upcoming February 2026 results, while the valuation gap to some fair value estimates and DRDGOLD’s history of paying dividends added to the appeal. The ERGO strike now sits squarely in the middle of that story. If it drags on, it could temporarily pressure volumes and margins at the very asset investors rely on to support those earnings and dividends. If it proves short lived, the longer term thesis may be mostly unchanged.
However, the labour dispute at ERGO could reshape expectations faster than many investors realise. Despite retreating, DRDGOLD's shares might still be trading 48% above their fair value. Discover the potential downside here.Explore 7 other fair value estimates on DRDGOLD - why the stock might be worth over 2x more than the current price!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com